Cross-Market Price Comparison
| Other Listed Market | Shanghai (SSE) — 药明康德 |
|---|---|
| Other Market Stock Code | 603259 |
| H-Share Offer Price | To be extracted |
| Other Market Price | Loading... |
| Reference Exchange Rate | Loading... |
| H-Share Offer Price Premium/Discount vs Other Market | Loading... |
Company Overview
| Stock Name | Wuxi Apptec |
|---|---|
| Stock Code | 02359 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 全球領先的藥物研發服務平台,提供全面配套的研究及生產服務,全面覆蓋小分子藥物的發現、開發及生產流程,同時提供細胞及基因療法的研發和生產服務,並提供醫療器械檢測服務。 |
| Listing Date | 2018-12-13 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國 上海 外高橋自貿區 富特中路288號 |
| Business Address (Hong Kong) | 香港 皇后大道東183號 合和中心54樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | www.wuxiapptec.com.cn |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | Yes (A股) |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 68.00 / shares |
| Offer Price Range | To be extracted |
| Lot Size | 100 shares |
| Entry Threshold | To be extracted |
| Par Value | RMB 1.0 / shares |
| Offer Period | 2018-12-03 to 2018-12-06 |
| Global Offering Shares | 116,474,200 shares |
| HK Public Offer Shares (Initial) | 11,647,600 shares (10.0%) |
| Public Offer Lots (Initial) | 116,476lots (Pool A58,238lots,Pool B58,238lots) |
| International Placing Shares (Initial) | 104,826,600 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 1,164,741,086 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | No cornerstone investors |
| Clawback Tiers | To be extracted |
| Reallocation Option | No |
| Total Global Offering Size | HK$ 7,920,245,600 |
Stock Connect Inclusion Analysis
| HK Market Cap | HK$ 85.07B |
|---|---|
| Analysis Result | Already included in Stock Connect (both) |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | 盈利約人民幣1,296.7百萬元 |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2015 | 2016 | 2017 | 2018-06 |
|---|---|---|---|---|
| Revenue | 4,883,349 | 6,116,131 | 7,765,260 | 4,409,207 |
| Cost of sales | -3,204,718 | -3,633,640 | -4,525,340 | -2,653,098 |
| Gross profit | 1,678,631 | 2,482,491 | 3,239,920 | 1,756,109 |
| Other income and gains, net | 387,441 | 236,873 | 173,779 | 444,361 |
| Selling and distribution expenses | -185,807 | -200,439 | -291,510 | -152,680 |
| Administrative expenses | -851,769 | -834,862 | -986,540 | -435,261 |
| Operating profit | 858,867 | 1,441,018 | 1,689,807 | 1,440,652 |
| Net finance costs | -28,125 | -16,360 | -48,547 | -45,521 |
| Share of associates and JVs | -29,393 | -42,483 | -48,640 | 29,900 |
| Profit before tax | 801,349 | 1,382,175 | 1,592,620 | 1,425,031 |
| Income tax expense | -117,570 | -261,202 | -295,900 | -120,961 |
| Profit for the year | 683,779 | 1,120,973 | 1,296,720 | 1,304,070 |
| Profit attributable to owners | 348,968 | 974,980 | 1,227,093 | 1,271,898 |
Balance Sheet
| Item | 2015 | 2016 | 2017 | 2018-06 |
|---|---|---|---|---|
| Cash and cash equivalents | 1,002,065 | 2,507,299 | 2,466,144 | 1,380,355 |
| Trade and bills receivables | 1,240,612 | 1,336,901 | 1,752,807 | 2,026,861 |
| Inventories | 208,411 | 444,587 | 649,815 | 772,105 |
| Total current assets | 6,358,713 | 6,043,710 | 5,470,201 | 7,401,966 |
| Total assets | 9,686,431 | 10,590,683 | 12,580,447 | 16,140,664 |
| Total current liabilities | 2,992,177 | 4,201,345 | 4,619,423 | 4,694,852 |
| Total liabilities | 3,256,308 | 4,528,278 | 5,842,436 | 5,806,028 |
| Total equity | 6,430,123 | 6,062,405 | 6,738,011 | 10,334,636 |
| Equity attributable to owners | 3,367,667 | 5,569,173 | 6,342,380 | 9,922,001 |
| Interest-bearing borrowings | 172,000 | 489,385 | 1,618,189 | 1,756,660 |
Cash Flow Statement
| Item | 2015 | 2016 | 2017 | 2018-06 |
|---|---|---|---|---|
| Net cash from operating activities | 738,596 | 1,761,308 | 1,795,648 | 420,733 |
| Net cash from investing activities | -933,281 | 383,995 | -1,132,344 | -3,682,834 |
| Net cash from financing activities | 428,512 | -721,489 | -668,177 | 2,201,402 |
| Net increase in cash | 233,827 | 1,423,814 | -4,873 | -1,060,699 |
| Depreciation of PP&E | 359,492 | 364,482 | 439,896 | 275,920 |
| Amortisation of intangible assets | 25,886 | 33,168 | 34,384 | 21,382 |
| Purchase of PP&E | -896,771 | -933,899 | -1,352,467 | -739,505 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 68.0 |
|---|---|
| First Day Open | HK$ 67.0 |
| First Day Change | 88.09% |
| First Day Volume | 20214000.0 |
| First Day Turnover | 1355050000.0 |
| Use of Proceeds | 1、約36.9%(即約2,798.0百萬港元)用于擴大全球所有業務單位的生產力及能力;
2、約26.5%(即約2,000.0百萬港元)用于收購CRO及CMO/CDMO公司;
3、約4.0%(即約300.0百萬港元)用于投資及培育健康業界有創新業務模式且有增長潛力的公司,以投資我們的生態體系;
4、約2.6%(即約200.0百萬港元)用于開發高端科技;
5、約19.9%(即約1,500百萬港元)用于償還最后可行日期的未償還選定銀行貸款;
6、約10.0%(即約755.3百萬港元)撥作營運資金及一般公司用途。 |
Underwriting Syndicate
Joint Sponsors (3)
Overall Coordinators (5)
Joint Bookrunners (8)
Morgan Stanley Asia Limited CE AAD291
HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536
UBS Securities Hong Kong Limited CE BIN466
CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650
China Renaissance Securities (Hong Kong) Limited CE AZX839
中银国际亚洲有限公司 CE AET863
CLSA LIMITED CE AAB893
Cornerstone Investors
This stock has no cornerstone investors.
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 李革 | — |
| Company Secretary | 姚馳 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 李革、趙寧、張朝暉、劉曉鐘為一致行動人,合共持有323,359,483股A股,佔約30.85%;其他主要股東包括G&C VI Limited(7.73%)、光輝月光有限公司(8.48%)、博裕系列(6.86%)、淡馬錫(7.77%)等。 |
|---|




